

## **CURRICULUM VITAE**

**Dr. Xavier Maseras Bruguera**



## 1. TRAINING

- 2016** PhD degree award Excellent Cum Laude  
**Universidad Autónoma Barcelona.**
- 2014** Postgraduate studies in Clinic management tools  
**Universitat Oberta de Catalunya**
- 2007 - 2009** Retina and Vitreoretinal surgery Fellowship  
**Institut Català de Retina. Universidad de Barcelona**
- 2007** Minimum research capacity  
**Universitat Autònoma de Barcelona**
- 2007** Clinical Sciences Assesment  
**International Council of Ophthalmology**
- 2006** Basic Sciences Assesment  
**International Council of Ophthalmology**
- 2003** PhD courses  
**Universidad Autónoma de Barcelona**
- 2003 – 2007** Residency in Ophthalmology  
**Hospital Sagrat Cor - Institut Català de Retina, Barcelona**
- 1995 – 2001** Degree in medicine and surgery  
**Universidad Autónoma de Barcelona –  
Hospital Germans Trias i Pujol, Barcelona**

## 2. PROFESIONAL EXPERIENCE

- 2009 – Present**      **Doctor member of the Retina and Vitreous Department of the Institut Català de Retina**
- 2015**                      “Observership” one month at the Manchester Eye Hospital, Manchester, United Kingdom
- 2012 – Present**      Colaboration in the Ophthalmology nursery Master, Universidad de Barcelona
- 2011**                      “Observership” one month at Tennessee Retina, Nashville, United States
- 2007**                      “Observership” one month at the Princess Margaret Hospital, Toronto, Canada
- 2001**                      Emergency department, Mutua del Carme, Granollers, Barcelona

## 3. LANGUAGES

- Spanish, Catalan, English and French

## 4. PUBLICATIONS

- Subfoveal choroidal thickness changes in carotid cavernous fistula following spontaneous resolution. BMC Ophthalmol. 2016 May 26;16:63
- Surgical outcome of late in-the-bag intraocular lens dislocation treated with pars plana vitrectomy Retina. 2016 Mar;36(3):576-81.

- Chapter “Angiografía Fluoresceínica” in Update in diabetic macular edema, Comunicación digital Solicitada de la Sociedad Catalana de Oftamologia 2016
- Natural course and surgical management of high myopic foveoschisis. Ophthalmologica. 2014;231(1):45-50.
- Chapter “Melanocitoma” in update in intraoculars tumors 2013 ( ISBN: 978-84-941074-9-8)
- Chapter “Vitreotomía 25G” in the book Macular disease and Surgery, Sociedad Española de Oftalmología 2010 ( ISBN: 978-84-89085-44-2)
- Clinical report “ paciente con pérdida visual unilateral” Published in Annals de Oftalmología, Vol 14 Num 3 2006
- Artículo de Revisión “Facomatosis y Oftalmologia “ Published in Annals de Oftalmología, Vol 16, Num 3 2008

## 5. CLINICAL TRIALS

- Safety, tolerability an efficacy study of XXX versus YYY in the treatment of exudative age-related macular degeneration. Promotor: Alcon. Time:2011-12
- Ensayo clinico en fase IV para evaluar la eficacia de aflibercept en pacientes con degeneración macular asociada a la edad (DMAE) neovascular, sin respuesta Optima a repetidas inyecciones mensuales intravitreas de XXX Estudio MACBETH. Promotor: Barcelona Macula Foundation. Time: 2013-2015.
- Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of XXX Ophthalmic Suspension For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery. Promotor: Alcon.
- Time: 2013-2014
- Assessment of Anatomical and Functional Outcomes in Patients Treated with XXX for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA). Promotor.Alcon. Periodo: 2014-2016.
- Ensayo controlado fase 3, aleatorizado, doble ciego, para establecer la seguridad y eficacia de la administración de XXX administrado en combinación con YYY o ZZZ comparado con YYY o ZZZ en monoterapia en sujetos con degeneración macular asociada a la edad neovascular subfoveal. Promotor OPTHOTECH Corp.Periodo: 2014-2017.
- A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of XXX Versus YYY in Subjects with

Neovascular Age-Related Macular Degeneration. Promotor ALCON.  
Periodo: 2015-2018.

- Efficacy and Safety of the Biosimilar XXX in comparison to YYY in patients with Neovascular Age-Related Macular Degeneration. Promotor: Bioeq GmbH. Period: 2016-2018